Movano has announced the completion of functional testing of its patented system-on-a-chip (SoC) for non-invasive glucose and cuffless blood pressure monitoring.
Measuring 4 mm × 6.7 mm, the SoC is said to be the smallest ever radio frequency (RF)-enabled integrated circuit (IC) combining multiple antennas and a variety of frequencies, .
The healthcare technology provider took four years to complete the development of the non-invasive sensor technology for enhanced precision in health monitoring.
Movano CEO Dr. John Mastrototaro said: “The majority of current wearables on the market use off-the-shelf optical sensors, whereas Movano has made a significant investment into creating its own fully integrated mmWave sensor simply because the standard approach cannot deliver the level of accuracy, flexibility of form factor or cost we are aiming to achieve.
“RF offers the opportunity for increased accuracy in health monitoring across a broader population because it is not affected by different skin pigmentation, as can be the case with optical sensors.”
The new sensor design has reduced the company’s multi-chip architecture from four ICs into a single integrated sensor.
Along with the completion of the sensor testing, Movano has been awarded a new patent, bringing its total number of its US patents to seven.
The new patent is expected to protect Movano’s multi-band semiconductor architecture, which employs signal diversity and superior signal processing capabilities.
The new design is anticipated to be integrated into various future devices.
Mastrototaro said: “In addition, our solution is fabricated using the latest processes in semiconductor technology, meaning the size can be smaller and the materials more cost-effective – giving us greater flexibility in the design of future medical devices and in our ability to offer a solution that’s affordable, so we can reach a larger, more diverse segment of people.
“In preparation for additional clinical studies, we’re integrating the SoC into a new, smaller prototype system to make further advancements on our quest to accurately measure blood pressure and glucose.”
In January this year, the firm announced the completion of an Institutional Review Board (IRB)-approved blood pressure clinical study.
